Caribou Biosciences (CRBU) Stock Forecast & Price Target

Caribou Biosciences is positioned favorably because its chRDNA platform is viewed as differentiated, more specific, and less encumbered by legacy IP issues, while Pfizer’s $25 million equity investment adds external validation. Its focus on validated targets like CD19 and BCMA, along with engineering features such as PD1 knockout, HLA-E knock-in, and TRAC/B2M insertion, supports the view that it can improve T-cell persistence and durability versus other allogeneic CAR-T programs. With the stock trading close to cash and clinical data expected in 2H25, the company offers what appears to be limited downside and meaningful upside potential if responses prove stronger than historical controls.

Caribou Biosciences is viewed negatively because it is effectively halting all clinical development of its two allogeneic CAR-T programs, vispa-cel and CB-011, after citing a challenging financing environment and insufficient capital availability. The decision to explore strategic alternatives, including a merger or acquisition, signals that the core pipeline has not generated enough confidence or funding support to continue independently, while most discontinuation and workforce reductions are not expected to be completed until 4Q26. With only $113.8 million in cash, cash equivalents, and marketable securities as of June 30, 2026, and downside assumptions implying 0% probability of success across programs and the platform, the business case has materially weakened.